CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Retrospective analysis supports erenumab in trigeminal neuralgia

| News

Improved pain scores and mood have been reported by patients with trigeminal neuralgia (TN) who were treated with erenumab. Nine out of 10 patients diagnosed with TN and treated with erenumab for six months reported improvement in pain severity according to a numeric pain rating scale (NPRS) from 0 to 10, and in global mood.

Three patients reported resolution of anxiety, and/or depression. Side effects were minimal with three patients reporting constipation, injection site reactions or both.

The authors stress that this is class IV evidence but conclude that erenumab increased the probability of improved pain control in patients with medication resistant trigeminal neuralgia.

 

Reference

Parascandolo E, Levinson K, Rizzoli P, Sharon R. Efficacy of Erenumab in the Treatment of Trigeminal Neuralgia: A Retrospective Case Series. Neurol Clin Pract. Published online 1 Apr 2021